Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Bayer

< Previous 1 2 3 4 5 6 7 8 Next >
Bayer Announces Recipients of the Second Annual Pulmonary Hypertension Accelerated Awards
From Bayer
Via Business Wire
Bayer to Highlight Expanded Research from Growing Oncology Portfolio at ESMO Congress 2021
From Bayer
Via Business Wire
Bayer and Luke Bryan Team Up Again for “Here’s to the Farmer” Campaign
From Bayer
Via Business Wire
Bayer Starts Phase III Clinical Development Program OASIS With Investigational Product, Elinzanetant
From Bayer
Via Business Wire
Bayer Announces KERENDIA® (finerenone) Reduces the Risk of Cardiovascular Outcomes in New Phase III FIGARO-DKD Study in Adults With Chronic Kidney Disease (Stages 1-4) Associated With Type 2 Diabetes
From Bayer
Via Business Wire
FDA Label Updates Reflect Bayer’s Commitment to Women’s Healthcare
From Bayer
Via Business Wire
Bayer Announces Filing of Petition to U.S. Supreme Court for Review of Hardeman Decision
From Bayer
Via Business Wire
Bayer Strengthens Drug Discovery Platform Through Acquisition of Vividion Therapeutics
From Bayer
Via Business Wire
Bayer Provides Update on Path to Closure of Roundup™ Litigation
From Bayer
Via Business Wire
Denise Vitola Joins Bayer Communications Team
From Bayer
Via Business Wire
Bayer Once Again Earns Top Marks in 2021 Disability Equality Index
From Bayer
Via Business Wire
Bayer’s KERENDIA® (finerenone) Receives U.S. FDA Approval for Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes
From Bayer
Via Business Wire
Bayer’s KERENDIA® (finerenone) Receives U.S. FDA Approval for Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes
From Bayer
Via Business Wire
Bayer Submits Regulatory Applications for Oncology Treatment Investigational Combination of Aliqopa® (copanlisib) and rituximab in the U.S. and EU
From Bayer
Via Business Wire
FDA Approves Astepro® Allergy Nasal Spray for Over-the-Counter Use in the United States
From Bayer
Via Business Wire
ZERO – The End of Prostate Cancer and Bayer Band Together with Twisted Sister’s Jay Jay French to Raise Awareness about Prostate Cancer Screening and Treatment
From Bayer
Via Business Wire
Bayer Announces First ‘Precision Oncology Patient Innovation Awards’
From Bayer
Via Business Wire
Bayer to Advance Two First-of-its-Kind Investigational Cell and Gene Therapies for Parkinson’s Disease
From Bayer
Via Business Wire
Bayer Acquires Noria and PSMA Therapeutics to Expand Pipeline in Prostate Cancer
From Bayer
Via Business Wire
Bayer announces five-point plan to effectively address potential future Roundup™ claims
From Bayer
Via Business Wire
Long-term Data on Vitrakvi® (larotrectinib) Further Demonstrate Strong Clinical Profile in Patients with TRK Fusion Cancer Regardless of Tumor Type and Age
From Bayer
Via Business Wire
Bayer Announces New Commercial Leaders for Crop Science Division to Accelerate Growth and Drive Business Transformation
From Bayer
Via Business Wire
Bayer Presents Latest Data and New Research to Advance Cancer Care within Oncology Portfolio at 2021 ASCO Annual Meeting
From Bayer
Via Business Wire
Bayer’s Finerenone Meets Primary Endpoint in Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes
From Bayer
Via Business Wire
Bayer Pharmaceuticals Taps Two Leaders for New Roles in the U.S.
From Bayer
Via Business Wire
Enhanced Bayer Carbon Program Offers Growers New Opportunities in 2021 and Beyond
From Bayer
Via Business Wire
Investigational Combination of Aliqopa® (copanlisib) and rituximab Significantly Increases Progression-Free Survival in Patients with Relapsed Indolent non-Hodgkin's Lymphoma
From Bayer
Via Business Wire
Bayer to Present New Clinical Data in Indolent non-Hodgkin's Lymphoma and Additional Research on its Oncology Portfolio at AACR Annual Meeting 2021
From Bayer
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.